About The Oncology Institute, Inc.
https://theoncologyinstitute.comThe Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support.
CEO
Daniel Virnich
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:4.55M
Value:$15.23M
BLACKROCK, INC.
Shares:3.43M
Value:$11.51M
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:3.36M
Value:$11.26M
Summary
Showing Top 3 of 113
About The Oncology Institute, Inc.
https://theoncologyinstitute.comThe Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $136.56M ▲ | $26.97M ▼ | $-16.5M ▲ | -12.09% ▲ | $-0.14 ▲ | $-12.86M ▼ |
| Q2-2025 | $119.8M ▲ | $28.71M ▲ | $-17.01M ▲ | -14.2% ▲ | $-0.15 ▲ | $-9.41M ▲ |
| Q1-2025 | $104.41M ▲ | $27.16M ▲ | $-19.59M ▼ | -18.76% ▼ | $-0.21 ▼ | $-12.23M ▼ |
| Q4-2024 | $100.27M ▲ | $26.57M ▼ | $-13.18M ▲ | -13.15% ▲ | $-0.14 ▲ | $-10.31M ▲ |
| Q3-2024 | $99.9M | $28.22M | $-16.11M | -16.13% | $-0.18 | $-12.28M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $27.66M ▼ | $163.62M ▲ | $175.89M ▲ | $-12.27M ▼ |
| Q2-2025 | $30.29M ▼ | $159.8M ▼ | $168.78M ▲ | $-8.98M ▼ |
| Q1-2025 | $39.74M ▼ | $164M ▼ | $158.93M ▼ | $5.07M ▲ |
| Q4-2024 | $49.67M ▲ | $172.72M ▼ | $169.13M ▲ | $3.59M ▼ |
| Q3-2024 | $47.4M | $179.18M | $163.7M | $15.48M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.5M ▼ | $-12.63M ▼ | $-604K ▲ | $10.6M ▲ | $-2.63M ▲ | $-13.23M ▼ |
| Q2-2025 | $-13.99M ▲ | $-10.2M ▼ | $-1.21M ▼ | $1.96M ▲ | $-9.45M ▲ | $-11.41M ▼ |
| Q1-2025 | $-19.59M ▼ | $-4.99M ▼ | $-202K ▲ | $-4.74M ▼ | $-9.93M ▼ | $-5.32M ▼ |
| Q4-2024 | $-13.18M ▲ | $4.19M ▲ | $-1.75M ▼ | $-164K ▲ | $2.27M ▼ | $2.43M ▲ |
| Q3-2024 | $-16.11M | $819K | $10.4M | $-243K | $10.98M | $1.22M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Capitated Revenue | $10.00M ▲ | $40.00M ▲ | $20.00M ▼ | $20.00M ▲ |
 Clinical Research Trials And Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Dispensary Revenue | $50.00M ▲ | $90.00M ▲ | $50.00M ▼ | $60.00M ▲ |
 Fee For Service | $30.00M ▲ | $70.00M ▲ | $40.00M ▼ | $40.00M ▲ |
 Health Care Patient Service | $50.00M ▲ | $100.00M ▲ | $50.00M ▼ | $60.00M ▲ |
CEO
Daniel Virnich
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 46
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:4.55M
Value:$15.23M
BLACKROCK, INC.
Shares:3.43M
Value:$11.51M
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:3.36M
Value:$11.26M
Summary
Showing Top 3 of 113